Spero Therapeutics Inc (NASDAQ:SPRO) saw a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 361,200 shares, an increase of 14.2% from the September 30th total of 316,200 shares. Based on an average daily volume of 38,000 shares, the days-to-cover ratio is currently 9.5 days. Approximately 3.1% of the company’s shares are short sold.
Several analysts recently weighed in on the stock. TheStreet cut shares of Spero Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, July 29th. Cowen reaffirmed a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, November 5th. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 12th. Oppenheimer cut their price target on shares of Spero Therapeutics from $30.00 to $20.00 in a research report on Wednesday, October 2nd. Finally, Janney Montgomery Scott assumed coverage on shares of Spero Therapeutics in a research report on Monday, September 9th. They set a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Spero Therapeutics has an average rating of “Buy” and an average price target of $23.50.
Several institutional investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. grew its position in shares of Spero Therapeutics by 20.0% during the 3rd quarter. D.A. Davidson & CO. now owns 12,000 shares of the company’s stock valued at $127,000 after acquiring an additional 2,000 shares during the period. Rhumbline Advisers grew its position in shares of Spero Therapeutics by 10.9% during the 3rd quarter. Rhumbline Advisers now owns 15,042 shares of the company’s stock valued at $159,000 after acquiring an additional 1,481 shares during the period. Marshall Wace LLP grew its position in shares of Spero Therapeutics by 475.8% during the 2nd quarter. Marshall Wace LLP now owns 17,699 shares of the company’s stock valued at $204,000 after acquiring an additional 14,625 shares during the period. Novo Holdings A S bought a new position in shares of Spero Therapeutics during the 2nd quarter valued at approximately $5,363,000. Finally, Vanguard Group Inc. grew its position in shares of Spero Therapeutics by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 437,204 shares of the company’s stock valued at $5,032,000 after acquiring an additional 18,814 shares during the period. 50.98% of the stock is owned by hedge funds and other institutional investors.
SPRO traded down $0.04 during trading on Friday, reaching $10.22. 21,200 shares of the stock traded hands, compared to its average volume of 29,207. The company has a quick ratio of 6.90, a current ratio of 6.90 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $199.70 million, a PE ratio of -3.93 and a beta of 2.09. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The stock’s 50-day moving average is $10.67 and its 200 day moving average is $10.93.
Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.95) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.85) by ($0.10). The firm had revenue of $4.64 million during the quarter, compared to analysts’ expectations of $2.03 million. Spero Therapeutics had a negative net margin of 287.11% and a negative return on equity of 43.10%. As a group, equities research analysts anticipate that Spero Therapeutics will post -3.11 EPS for the current year.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.
Featured Story: Swap
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.